Could a tiny HPV shot still protect? small study tests lower dose
NCT ID NCT04235257
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a smaller, one-fifth dose of the HPV vaccine, given into the skin instead of the muscle, can still trigger a good immune response in adults aged 27 to 45. Researchers are comparing two types of HPV vaccines in 40 volunteers in Seattle. The goal is to see if a lower dose could be a practical option for expanding vaccine access.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HPV vaccine (Gardasil 9 or bivalent HPV VLP vaccine), given as a one-fifth dose into the skin
What this could lead to
If successful, this could show that a smaller, cheaper dose of HPV vaccine is effective, potentially making vaccination more accessible for adults.
What could go wrong
This is a very small early-phase trial with only 40 participants, so results may not apply to the general population. The fractional dose might not produce a strong enough immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Washington Virology Research Clinic
Seattle, Washington, 98104, United States